SLC5A2 and type 2 diabetes mellitus: After decades of disappointment in attempting to control cardiovascular disease progression in type 2 diabetes with careful glycemic control,a new found hope that newer drugs, particularly the Glucagon like peptide 1 receptor (GLP-1) agonist and the sodium glucose co transporter 2 SGLT-2 inhibitors have cardiovascular benefits independent of glycemic control has led to a new dimension in the management of type 2 diabetes.3 Despite its role in glucose homeostasis, the GLP-1 receptor is amazingly widely distributed throughout the body, including heart.